Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.60 |
| ▸ | PDE8B | O95263 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20828130 | 1.00 | ATM (0.60) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL2687901 | 1.00 | ATM (0.60) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL13381365 | 0.95 | ATM (0.58) | ATMPDE8BHSD17B10ALDH1A1MEN1 | |
| SCHEMBL16983241 | 0.95 | ATM (0.58) | ATMPDE8BHSD17B10ALDH1A1MEN1 | |
| SCHEMBL2689324 | 0.91 | ATM (0.52) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL28483278 | 0.90 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL15481739 | 0.89 | ATM (0.54) | ATMHSD17B10ALDH1A1HPGDMEN1 | |
| SCHEMBL2687739 | 0.89 | ATM (0.50) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL1551631 | 0.88 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10ALDH1A1 | |
| SCHEMBL2345014 | 0.88 | ATM (0.51) | ATMPDE8BKDM1AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-08-05 | — | — | US | disclosed |
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3681862-B1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2022-08-30 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2022-06-23 | — | — | US | disclosed |
| CN-113784961-A | Heteroaryl (heterocyclyl) carbinol compounds useful for treating hyperglycemia | 阿托基公司 | 2021-12-10 | — | — | CN | disclosed |
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2020-09-03 | — | — | US | disclosed |
| CN-111164072-A | β -hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | 阿托基公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019053425-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277259-A1 | BETA-HYDROXY HETEROCYCLIC AMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | ATM 1468/4885PDE8B 1602/4885KDM1A 1284/4885 |
| US-11427539-B2 | Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | ATM 1468/4885PDE8B 1602/4885KDM1A 1284/4885 |
| US-12378216-B2 | Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia | SLC5A1, GPR119, SLC5A2 | ATM 2008/4885PDE8B 2719/4885KDM1A 1985/4885 |
| US-20220194920-A1 | HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA | SLC5A1, GPR119, SLC5A2 | ATM 2008/4885PDE8B 2719/4885KDM1A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.